Evaluating immune cell therapy potency

13 Sept 2022

This eBook from Agilent provides an overview of the current state of CAR T therapies, showcases the use of xCELLigence Real-Time Cell Analysis (RTCA) technology to evaluate the potency of novel adoptive cell therapies, and demonstrates how this technology can be incorporated into research and development as well as manufacturing workflows of cell therapies.